The melanoma-specific XMEL antigen is expressed in dysplastic naevi

Melanoma Research

Volumn 7, Issue 3, 1997, Pages 209-213

  Tron, V A ^a   Crawford, R ^a   Vielkind, J R ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

Author keywords

Melanoma; Monoclonal antibody; Naevus; Progression stages

Indexed keywords

GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY; TUMOR ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; DYSPLASTIC NEVUS; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; MELANOMA; PRIORITY JOURNAL;

EID: 0030744325     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-199706000-00004     Document Type: Article

References (21)

1. Rigel DS, Kopf AW, Friedman RJ. The rate of malignant melanoma in the United States: are we making an impact? J Am Acad Dermatol 1987; 17: 1050-1053.
2. Koh HK. Cutaneous melanoma. N Engl J Med 1991; 325: 171-182.
3. Clark WH Jr, Elder DE, Guerry D, et al. A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. Human Pathol 1984; 15: 1147-1165.
4. Vielkind JR, Kallman KD, Morizot DC. Genetics of melanomas in Xiphophorus fishes. J Aquatic Animal Health 1989; 1: 68-77.
5. Vielkind JR. Progression from pigment cell patterns to melanomas in platyfish -swordtail hybrids - multiple genetic changes and a theme for tumorigenesis. In: Milo GE, Casto BC, Shuler CF, eds. Transformation of Human Epithelial Cells: Molecular and Oncogenetic Mechanisms. Boca Raton, FL: CRC Press, 1992. 285-301.
6. Wittbrodt J, Adam D, Malitschek B, et al. Novel putative receptor tyrosine kinase encoded by the melanoma-inducing Tu locus in Xiphophorus. Nature 1989; 341: 415-421.
7. Woolcock BW, Schmidt BM, Kallman KD, Vielkind JR. Differences in transcription and promoters of Xmrk-1 and Xmrk-2 genes suggest a role for Xmrk-2 in pigment pattern development in the platyfish, Xiphophorus maculants. Cell Growth Differ 1994; 5: 575-583.
8. Vielkind JR, Tron VA, Schmidt B, et al. A putative marker for human melanoma - a monoclonal antibody derived from the melanoma gene in the Xiphophorus melanoma model. Am J Pathol 1993; 143: 656-62.
9. Clemente C, Cochran AJ, Elder DE, et al. Histopathological diagnosis of dysplastic nevi: concordance among pathologists convened by the World Health Organisation Melanoma Program. Hum Pathol 1991: 22: 313-319.
10. Breslow A. Thickness, cross-sectional area and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 1970; 172: 902-908.
11. Ruiter DJ, Dingjian GM, Steijen PM, et al. Monoclonal antibodies selected to discriminate between malignant melanomas and nevocellular nevi. J Invest Dermatol 1985; 85: 4-8.
12. Klein E, Steinmayer, Kaufmann D, et al. Identification of a melanoma progression antigen as integrin VLA-2. J Invest Dermatol 1991; 96: 281-284.
13. Johnson JR Stade BG, Holzmann B, et al. De novo expression of intercellular-adhesion molecule 1 in melanoma correlated with increased risk of metastasis. Proc Natl Acad Sci USA 1989; 86: 641-644.
14. Broecker EB, Suter L, Brueggen J, et al. Phenotypic dynamics of tumor progression in human malignant melanoma. Int J Cancer 1985; 36: 29-35.
15. Lehmann JM, Holzmann B, Breibart EW, et al. Discrimination between benign and malignant cells of melanocytic lineage by two novel antigens, a glycoprotein with a molecular weight of 113,000 and a protein with a molecular weight of 76,000. Cancer Res 1987; 47: 841-845.
16. Sachsenmaier C, Radler-Pohl A, Zinck R, et al. Involvement of growth factor receptors in the mammalian UVC response. Cell 1994; 78: 963-972.
17. Ackerman AB. What naevus is dysplastic, a syndrome, and the commonest precursor or malignant melanoma? A riddle and an answer. Histopathology 1988; 13: 241-256.
18. Clark WH, Elder DE, Guerry D IV, et al. A study of tumor progression. The precursor lesions of superficial spreading and nodular melanoma. Hum Pathol 1984; 15: 1147-1165.
19. Greene MH, Clark WH, Tucker MA, et al. High-risk malignant melanoma in melanoma-prone families with dysplastic nevi. Ann Intern Med 1985; 102: 458-465.
20. Rigel DS, Rivers JK, Kopf AW Friedman RJ, et al. Dysplastic nevi. Markers for increased risk for melanoma. Cancer 1989; 63: 386-389.
21. Gruber SB, Barnhill RL, Stenn KS, Roush GC. Nevomelanocytic proliferations in association with cutaneous malignant melanoma: a multivariate analysis. J Am Acad Dermatol 1989; 21: 773-780.